MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

On January 7, 2025 MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, reported that it has entered into a clinical supply agreement with global oncology company BeiGene to assess the efficacy of THIO, its small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor (CPI) tislelizumab in three cancer indications (Press release, MAIA Biotechnology, JAN 7, 2025, View Source [SID1234649486]). The single arm pivotal Phase 2 trials will study the drug combination in hepatocellular carcinoma (HCC), small cell lung cancer (SCLC) and colorectal cancer (CRC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MAIA’s preclinical results in HCC, with THIO in combination with a CPI, showed complete, durable and highly potent anti-tumor immune response. Preclinical results of THIO treatment in SCLC showed profound activation of innate and adaptive anti-tumor responses. In CRC pre-clinical studies, THIO administered in sequence with a CPI resulted in 100% complete response and anticancer immune memory was induced, resulting in no recurrence after rechallenge with 10x more CRC cells and no additional therapy. In all preclinical studies, THIO converted immunologically cold and non-responsive tumors into hot tumors that are responsive to a CPI.

"Based on excellent pre-clinical results, THIO was awarded orphan drug designation (ODD) for the treatment of both HCC and SCLC. Along with a third ODD in glioblastoma, the FDA has clearly recognized THIO’s potential as an effective treatment for multiple cancer indications. Comparatively, most oncology compounds at this stage of development have only one indication," said MAIA Chairman and Chief Executive Officer Vlad Vitoc, M.D. "BeiGene’s tislelizumab has also demonstrated its potential to deliver clinically meaningful outcomes across a range of tumor types. We are pleased to partner with BeiGene for these important studies, two of which address the top three most lethal cancers worldwide."

Under the terms of the collaboration, MAIA will sponsor and fund the planned clinical trials and BeiGene will provide tislelizumab. MAIA maintains global development and commercial rights to THIO and is free to develop the programs in combination with other agents and in other indications.

MAIA is targeting accelerated FDA approvals in each of the three indications to be studied along with non-small cell lung cancer (NSCLC), the focus of a current Phase 2 clinical trial of THIO with a CPI.

Market Trends

Hepatocellular carcinoma is the third most common cause of cancer-related deaths globally. The market for HCC was valued at $780 million in 2023 and is expected to increase to grow at a CAGR of 6.3% to $1.5 million by 2034.1

Small cell lung cancer accounts for an estimated 15% of all lung cancer globally. The global SCLC therapeutics market is valued at approximately $6.5 billion in 2024 and is expanding at an estimated CAGR of 12.3% from 2024 to 2034.2

Colorectal cancer is the second leading cause of cancer-related deaths globally.3 Approximately 85% of all CRC cases are classified as microsatellite stable. MSS tumors are "cold tumors" that typically do not trigger the body’s immune system. The global CRC therapeutics market size was $9.26 billion in 2018 and is projected to reach $26.49 billion by 2032.4

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors

On January 7, 2025 Biocytogen (HKEX: 02315) and Acepodia (6976:TT), reported a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program (Press release, Biocytogen, JAN 7, 2025, View Source [SID1234649485]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This collaboration combines Biocytogen’s RenLite platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology to tackle some of the toughest challenges in oncology—tumor heterogeneity and drug resistance. This novel approach aims to address these complexities by utilizing dual-payloads that target multiple therapeutic or disease pathways. These payloads are delivered with bispecific antibodies that enable enhanced precision and functionality.

As part of the strategic partnership, Biocytogen will provide a bispecific antibody derived from its proprietary RenLite platform, which is designed to produce fully human bispecific antibodies with unique binding properties. To this antibody, Acepodia will integrate two different payloads using its Antibody-Dual-Drugs Conjugation (AD2C) platform. This platform enables site-selective conjugation of multiple payloads to an antibody using bio-orthogonal click chemistry with no required antibody engineering, maintaining antibody integrity and binding capacity, and allowing strategic and precise control over the Drug-to-Antibody Ratio (DAR) for optimal potency and safety.

"We are thrilled to partner with the Acepodia team who brings deep expertise in bio-orthogonal click chemistry and the unique opportunity to combine our RenLite bispecific antibodies with site-selective dual-payload conjugates," said Dr. Yuelei Shen, President and CEO of Biocytogen. "We look forward to bridging our platforms to explore the therapeutic potential of highly potent BsADCs."

"Biocytogen’s superior bispecific antibodies and highly collaborative team make them an ideal partner for advancing our AD2C payload platform," said Sonny Hsiao, Ph.D., Co-Founder and CEO of Acepodia. "This partnership redefines the possibilities of ADC design, with the potential to deliver breakthrough therapies to patients in desperate need of new options."

This strategic partnership underscores the commitment of both companies to addressing the critical unmet needs in ADC drug development for solid tumors, paving the way for innovative therapies that improve patient outcomes

U.S. FDA Granted Priority Review to Dizal’s Sunvozertinib New Drug Application

On January 7, 2025 Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, reported that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the company’s New Drug Application (NDA) for sunvozertinib, an oral EGFR inhibitor for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy (Press release, Dizal Pharma, JAN 7, 2025, View Source [SID1234649481]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The FDA grants priority review to drugs that, if approved, would be significant improvements in the safety or effectiveness over existing treatment for a serious disease. This decision follows the FDA’s earlier Breakthrough Therapy Designations for Sunvozertinib in treatment naïve and relapsed or refractory settings. Currently, no small molecule drug has been approved in the U.S. or Europe to treat this serious disease.

The NDA submission is supported by efficacy and safety results from the multinational pivotal WU-KONG1 Part B study, evaluating sunvozertinib in relapsed or refractory NSCLC patients with EGFR exon20ins from Asia, Europe, North America, and South America. These data, presented at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, demonstrated statistically significant clinical benefits.

"Patients with EGFR exon20ins NSCLC face a poor prognosis and limited treatment options," said Xiaolin Zhang, PhD, CEO of Dizal. "Sunvozertinib’s Priority Review designation marks an important regulatory milestone in Dizal’s efforts to address unmet medical needs worldwide. The results from the WU-KONG1 Part B study are promising. If approved, sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins."

In 2023, Sunvozertinib was granted accelerated approval by the National Medical Products Administration (NMPA) of China, making it the world’s first and only oral treatment for NSCLC patients with EGFR exon20ins.

About Sunvozertinib (DZD9008)
Sunvozertinib is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. In August 2023, sunvozertinib received approval from NMPA to treat advanced NSCLC with EGFR exon20ins after platinum-based chemotherapies. The approval is based on the results of WU-KONG6 study, the pivotal study of sunvozertinib in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. In addition, sunvozertinib also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations (such as G719X, L861Q, etc.), as well as HER2 exon20ins.

Sunvozertinib showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse event) were Grade 1/2 in nature and clinically manageable.

Two global pivotal studies are ongoing in ≥ 2nd line (WU-KONG1 Part B) and 1st line setting (WU-KONG28), respectively, in NSCLC patients with EGFR exon20ins.

Pre-clinical and clinical results of sunvozertinib were published in peer-reviewed journals Cancer Discovery and The Lancet Respiratory Medicine.

Esphera SynBio closes seed financing round to develop nanomedicine vaccines for cancer and infectious disease

On January 7, 2025 Esphera SynBio ("Esphera"), a synthetic biology company, reported the closing of a $2M USD seed financing round (Press release, Esphera SynBio, JAN 7, 2025, View Source [SID1234649480]). The financing builds on the Company’s advanced R&D activities and proceeds are directed at the identification of an initial cancer vaccine clinical candidate and general corporate purposes. Seed investors GKCC and FACIT supported the financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Using synthetic biology, Esphera produces engineered exosomes through the expression of proprietary transgenes that serve as nanomedicines. Unlocking new possibilities in vaccine innovation, the company applies the technology platform for the development of therapeutics for cancer and infectious disease.

"This financing enables us to validate our vaccine platform and advance a potential best-in-class therapy for patients living with cancer," said Dr. Brian Lichty, co-founder and CEO of Esphera. "While our clear focus is on advancing toward future clinical trials, maximizing the broad potential of our technology will also necessitate the exploration of strategic partnerships."

Esphera’s innovative platform produces therapeutic nanomedicines that can act as powerful immunostimulants, delivering customized antigenic payloads to stimulate robust immune responses. These nanomedicines are designed to enhance the efficacy of vaccines, offering personalized solutions to combat infectious disease.

"With the fields of engineered exosomes and therapeutic vaccines undergoing rapid evolution, Esphera’s pioneering approach places the Company at the forefront of a transformative opportunity for patient care," said Dr. David O’Neill, Chair of the Board of Directors of Esphera and President of FACIT. "Esphera’s team of entrepreneurial scientific leaders has the experience required to build a strong pipeline of innovative therapeutics."

The Company is based on foundational intellectual property from the labs of Drs. Carolina Ilkow and John Bell at The Ottawa Hospital Research Institute and Dr. Lichty at McMaster University, and operates research facilities in Hamilton, Ontario and Ottawa, Ontario.

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib

On January 7, 2025 Johnson & Johnson (NYSE:JNJ) reported positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations (Press release, Johnson & Johnson, JAN 7, 2025, View Source [SID1234649479]). The chemotherapy-free combination regimen met the final pre-specified secondary endpoint of OS and demonstrated clinically meaningful and statistically significant improvement in OS versus the current standard of care osimertinib. Improvement in median OS is expected to exceed one year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Unlike progression-free survival (PFS), which tracks the time a treatment keeps a patient’s cancer from progressing, OS helps patients understand the impact therapy could have on the ability to live longer from the start of treatment. Extending life expectancy is the most meaningful indicator of a treatment’s impact.

"The combination of these two agents previously demonstrated an improvement in progression-free survival, but this does not always capture the impact on the entire treatment course. Evaluation of overall survival can better demonstrate the benefit of a first-line treatment regimen," said Stephen Liu, M.D.*, Associate Professor of Medicine at Georgetown University School of Medicine and Director of Thoracic Oncology and Head of Developmental Therapeutics at Georgetown’s Lombardi Comprehensive Cancer Center. "Seeing this increase in overall survival in a trial with mature data is powerful and reaffirms that first-line treatment with RYBREVANT and LAZCLUZE can lead to better patient outcomes."

"Every milestone in clinical trials and every approval of a new drug or regimen brings hope and progress for EGFR-positive patients and their families," said Marcia Horn**, President of International Cancer Advocacy Network. "These topline data from the MARIPOSA trial offer renewed optimism in the journey to extend life for EGFR-mutated patients, adding another important option for patients and oncologists."

"These new findings reinforce the clinically meaningful impact this chemotherapy-free regimen can have for patients worldwide with non-small cell lung cancer and represent the first overall survival benefit over the current standard of care," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. "With less than 20 percent of patients living beyond five years, an incredible unmet need remains for EGFR-positive lung cancer. These MARIPOSA results show RYBREVANT plus LAZCLUZE can extend survival beyond the current standard of care, providing patients with more time and hope in their fight against this devastating disease. Extending median overall survival by more than a year could be transformative for these patients."

Results from the final OS analysis build upon previously reported data from the interim analysis and positive results from the PFS analysis. MARIPOSA, which enrolled 1,074 patients, is a randomized, Phase 3 study evaluating RYBREVANT in combination with LAZCLUZE versus osimertinib as a first-line treatment of patients with EGFR-mutated NSCLC. The study’s primary endpoint was PFS (using RECIST v1.1 guidelines***) as assessed by blinded independent central review (BICR). Secondary endpoints included OS, objective response rate (ORR), duration of response (DOR), second progression-free survival (PFS2) and intracranial PFS.

The safety profile of RYBREVANT plus LAZCLUZE was generally consistent with the profiles of the individual treatments. Adverse event rates were consistent in this arm as compared to other RYBREVANT regimens. Venous thromboembolic events were observed with the combination. Subsequent studies showed that administering oral anticoagulant medicines prophylactically during the initial four months of the RYBREVANT and LAZCLUZE regimen significantly reduced the risk of thrombosis.

Due to the impact of these data on patient care, these OS results will be presented at an upcoming major medical meeting, and will be shared with global health authorities. RYBREVANT combined with LAZCLUZE is approved in the United States and Europe for the first-line treatment of patients with EGFR-mutated NSCLC based on the MARIPOSA Phase 3 study.

About RYBREVANT

RYBREVANT (amivantamab-vmjw), a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity, is approved in the U.S., Europe and other markets around the world as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.1

RYBREVANT is approved in the U.S., Europe and other markets around the world in combination with chemotherapy (carboplatin and pemetrexed) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.

RYBREVANT is approved in the U.S. and Europe in combination with LAZCLUZE (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R substitution mutations, as detected by an FDA-approved test.

RYBREVANT is approved in the U.S., Europe and other markets around the world in combination with chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitors (TKI).

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC§ prefer next-generation sequencing–based strategies over polymerase chain reaction–based approaches for the detection of EGFR exon 20 insertion variants. The NCCN Guidelines include:

Amivantamab-vmjw (RYBREVANT) plus lazertinib (LAZCLUZE) as a Category 1 recommendation for first-line therapy in patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.2†‡
Amivantamab-vmjw (RYBREVANT) plus chemotherapy as a Category 1 recommendation for patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations who experienced disease progression after treatment with osimertinib.2†‡
Amivantamab-vmjw (RYBREVANT) plus chemotherapy as a Category 1 recommendation for first-line therapy in treatment-naive patients with newly diagnosed advanced or metastatic EGFR exon 20 insertion mutation-positive advanced NSCLC.2†‡
Amivantamab-vmjw (RYBREVANT) as a Category 2A recommendation for patients that have progressed on or after platinum-based chemotherapy with or without an immunotherapy and have EGFR exon 20 insertion mutation-positive NSCLC.2†‡
For more information, visit: View Source

About LAZCLUZE

In 2018, Janssen Biotech, Inc., entered into a license and collaboration agreement with Yuhan Corporation for the development of LAZCLUZE (marketed as LACLAZA in Korea). LAZCLUZE is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild-type EGFR. An analysis of the efficacy and safety of LAZCLUZE from the Phase 3 LASER301 study was published in The Journal of Clinical Oncology in 2023.

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.3,4 The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.5 Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.6 EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.5,6,7,8,9,10 EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.11 The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR TKIs is less than 20 percent.12,13 EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.14 Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.15

IMPORTANT SAFETY INFORMATION1,16

Before you receive RYBREVANT as a single agent or in combination, tell your healthcare provider about all of your medical conditions, including if you:

have a history of lung or breathing problems.
are pregnant or plan to become pregnant. RYBREVANT and LAZCLUZE can harm your unborn baby.
Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with RYBREVANT or RYBREVANT in combination with LAZCLUZE.
You should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT.
For patients receiving LAZCLUZE: You should use effective birth control (contraception) during treatment and for 3 weeks after your last dose of LAZCLUZE.
Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT or LAZCLUZE.
Males who have female partners who are able to become pregnant:

You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE.
are breastfeeding or plan to breastfeed. It is not known if RYBREVANT passes into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT. It is not known if LAZCLUZE passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after your last dose of LAZCLUZE.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

LAZCLUZE may affect the way other medicines work, and other medicines may affect how LAZCLUZE works.

You should not start or stop any medicine before you talk with your healthcare provider that prescribed LAZCLUZE.

How will I receive RYBREVANT?

RYBREVANT will be given to you by your healthcare provider by intravenous infusion into your vein.
Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
Your healthcare provider will give you medicines before each dose of RYBREVANT to help reduce the risk of infusion-related reactions.
RYBREVANT may be given in combination with the medicines carboplatin and pemetrexed. If you have any questions about these medicines, ask your healthcare provider.
If your treatment with RYBREVANT is given in combination with LAZCLUZE (lazertinib), you should take your dose of LAZCLUZE by mouth anytime before your infusion with RYBREVANT.
If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
How should I take LAZCLUZE?

Take LAZCLUZE exactly as your healthcare provider tells you to take it.
Take LAZCLUZE one (1) time each day. On the day RYBREVANT is also given, take LAZCLUZE anytime before receiving the RYBREVANT infusion.
You can take LAZCLUZE with or without food.
Swallow LAZCLUZE tablets whole. Do not crush, cut, or chew the tablets.
If you miss a dose of LAZCLUZE and:
it has been less than 12 hours, take the missed dose.
it has been more than 12 hours, skip the dose and take your next dose at your regularly scheduled time.
If you vomit a dose of LAZCLUZE, do not take an extra dose. Take your next dose at your regularly scheduled time.
LAZCLUZE may be given in combination with other anti-cancer medicines. If you have any questions about these medicines, ask your healthcare provider.
What should I avoid while receiving RYBREVANT and/or LAZCLUZE?

RYBREVANT and RYBREVANT in combination with LAZCLUZE can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment with RYBREVANT and/or LAZCLUZE. Wear protective clothing and use sunscreen during treatment with RYBREVANT and/or LAZCLUZE.

What are the possible side effects of RYBREVANT or LAZCLUZE?

RYBREVANT and LAZCLUZE may cause serious side effects, including:

infusion-related reactions. Infusion-related reactions are common with RYBREVANT and can be severe or serious. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of RYBREVANT:

shortness of breath
fever
chills
nausea

flushing
chest discomfort
lightheadedness
vomiting

lung problems. RYBREVANT may cause lung problems that may lead to death. LAZCLUZE may also cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.

blood clot problems. Blood clots are a serious, but common side effect of RYBREVANT, when given together with LAZCLUZE, may cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death. Your healthcare provider will start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your healthcare provider right away if you have any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.

skin problems. RYBREVANT can cause severe rash; including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. LAZCLUZE may cause severe rash including redness, raised acne-like bumps, itching, and dry skin. You may use alcohol-free (isopropanol-free, ethanol-free) moisturizing cream to reduce the risk of skin problems. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with RYBREVANT or LAZCLUZE. See "What should I avoid while receiving RYBREVANT and/or LAZCLUZE?"

eye problems. RYBREVANT may cause eye problems. LAZCLUZE may also cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include:

eye pain
inflammation of eye lids
inflamed cornea (front part of the eye)
dry eyes
eye redness
blurred vision

changes in vision
itchy eyes
excessive tearing
sensitivity to light
new or worsening problems with vision
Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment with RYBREVANT or LAZCLUZE. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.

The most common side effects of RYBREVANT in combination with LAZCLUZE (lazertinib) include:

rash
infected skin around the nail
muscle and joint pain
sores in the mouth
swelling of hands, ankles, feet, face, or all of your body
unusual feeling in the skin (such as tingling or a crawling feeling)
feeling very tired

diarrhea
constipation
COVID-19
dry skin
bleeding
decreased appetite
itchy skin
nausea
changes in certain blood tests
The most common side effects of RYBREVANT when given in combination with carboplatin and pemetrexed include:

rash
infected skin around the nail
feeling very tired
nausea
sores in the mouth
constipation
swelling of hands, ankles, feet, face, or all of your body

decreased appetite
muscle and joint pain
vomiting
COVID-19
changes in certain blood tests
The most common side effects of RYBREVANT when given alone:

rash
infected skin around the nail
muscle and joint pain
shortness of breath
nausea
feeling very tired

swelling of hands, ankles, feet, face, or all of your body
sores in the mouth
cough
constipation
vomiting
changes in certain blood tests
LAZCLUZE may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

Your healthcare provider may temporarily stop, decrease your dose, or completely stop your treatment with RYBREVANT or LAZCLUZE if you have serious side effects.

These are not all of the possible side effects of RYBREVANT or LAZCLUZE.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of RYBREVANT:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

You can ask your healthcare provider or pharmacist for information about RYBREVANT that is written for health professionals.

General information about the safe and effective use of LAZCLUZE:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LAZCLUZE for a condition for which it was not prescribed. Do not give LAZCLUZE to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about LAZCLUZE that is written for health professionals.

Please read full Prescribing Information for RYBREVANT.

Please read full Prescribing Information for LAZCLUZE.